Case Study: EEG Digital Biomarkers in Neuropsychiatric Clinical Studies

Healthcare > Clinical Trials2/15/2024 5:00 PM

Go to Registration Page


Discover an informative webinar discussing digital biomarkers in neuropsychiatric trials, leveraging an artificial intelligence (AI)-driven platform for enhanced treatment outcomes. Drugs for psychiatric conditions suffer some of the lowest approval rates when compared to other major therapeutic areas. Underlying factors can include complex and poorly understood etiology, which are heterogeneous in presentation, and underlying pathophysiology. Additionally, traditional clinical studies fail to objectively assess cognitive function as part of patient eligibility criteria or stratify patients according to the presence or degree of cognitive impairment. Cognitive function assessments and electroencephalogram (EEG) enable the measurement of pharmacodynamic endpoints in early-stage, translational psychiatric studies, however many studies do not leverage these tools today.


Rate This Webinar

community rating (0 votes): 
Rate or Review This Webinar


Cumulus Neuroscience

Cumulus Neuroscience

Cumulus Neuroscience is developing fast and effective tools to help partners solve the biggest healthcare challenges in neurodegeneration and psychiatry. Their platform is designed to be the gold-standard for CNS assessments, providing critical data and insights for faster and more robust clinical trials. With their integrated platform, they combine clinical-grade, at-home data collection with powerful machine learning analytics. Their goal is to transform the future of clinical trials in brain disorders and bring life-changing therapies to patients faster and more cost-effectively.